File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Use of anti-vascular endothelial growth factor in the management of pterygium

TitleUse of anti-vascular endothelial growth factor in the management of pterygium
Authors
Issue Date2016
Citation
Acta Ophthalmologica, 2016 How to Cite?
AbstractThe rising success of anti-vascular endothelial growth factor (VEGF) therapies in ocular disease has stimulated the use of such treatments in the surgical management of pterygium. We reviewed the literature to better understand the safety and efficacy of the adjunctive role of anti-VEGF treatments for pterygium excision. Without surgery, anti-VEGF alone may favourably alter symptoms and vascularity, but does not cause pterygium regression. Some evidence supports the use of anti-VEGF as an adjuvant therapy to surgery, especially when using a higher dose and a more frequent dosing regimen. Overall, anti-VEGF is generally safe and well tolerated in patients with pterygium. Currently, the evidence does not conclusively support the use of anti-VEGF in pterygium surgery. However, further research may guide unanswered questions regarding the interaction between VEGF and other factors responsible for pterygium growth. In addition, the optimal route and dosage of anti-VEGF administration is not yet known
Persistent Identifierhttp://hdl.handle.net/10722/230580

 

DC FieldValueLanguage
dc.contributor.authorMak, RK-
dc.contributor.authorChan, TCY-
dc.contributor.authorMarcet, MM-
dc.contributor.authorChoy, NKB-
dc.contributor.authorShum, JWH-
dc.contributor.authorShih, KC-
dc.contributor.authorWong, YHI-
dc.contributor.authorNg, LK-
dc.date.accessioned2016-08-23T14:17:52Z-
dc.date.available2016-08-23T14:17:52Z-
dc.date.issued2016-
dc.identifier.citationActa Ophthalmologica, 2016-
dc.identifier.urihttp://hdl.handle.net/10722/230580-
dc.description.abstractThe rising success of anti-vascular endothelial growth factor (VEGF) therapies in ocular disease has stimulated the use of such treatments in the surgical management of pterygium. We reviewed the literature to better understand the safety and efficacy of the adjunctive role of anti-VEGF treatments for pterygium excision. Without surgery, anti-VEGF alone may favourably alter symptoms and vascularity, but does not cause pterygium regression. Some evidence supports the use of anti-VEGF as an adjuvant therapy to surgery, especially when using a higher dose and a more frequent dosing regimen. Overall, anti-VEGF is generally safe and well tolerated in patients with pterygium. Currently, the evidence does not conclusively support the use of anti-VEGF in pterygium surgery. However, further research may guide unanswered questions regarding the interaction between VEGF and other factors responsible for pterygium growth. In addition, the optimal route and dosage of anti-VEGF administration is not yet known-
dc.languageeng-
dc.relation.ispartofActa Ophthalmologica-
dc.titleUse of anti-vascular endothelial growth factor in the management of pterygium-
dc.typeArticle-
dc.identifier.emailMarcet, MM: marcet@hku.hk-
dc.identifier.emailChoy, NKB: bnkchoy@hku.hk-
dc.identifier.emailShum, JWH: jenni101@hku.hk-
dc.identifier.emailShih, KC: kcshih@hku.hk-
dc.identifier.emailWong, YHI: wongyhi@hku.hk-
dc.identifier.emailNg, LK: nlk008@hku.hk-
dc.identifier.authorityMarcet, MM=rp01363-
dc.identifier.authorityChoy, NKB=rp01795-
dc.identifier.authorityShum, JWH=rp01849-
dc.identifier.authorityShih, KC=rp01374-
dc.identifier.authorityWong, YHI=rp01467-
dc.identifier.authorityNg, LK=rp01842-
dc.identifier.doi10.1111/aos.13178-
dc.identifier.pmid27473792-
dc.identifier.hkuros262272-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats